HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Surgimend

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Macromolecular Substances: 97
- Polymers: 13051
  - Biopolymers: 773
    - Collagen: 52417
      - Surgimend: 5
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Scleroproteins: 74
    - Extracellular Matrix Proteins: 3148
      - Collagen: 52417
        Surgimend: 5

Experts

1.	Brunnert, Klaus: 1 article (06/2015)
2.	Eichler, Christian: 1 article (06/2015)
3.	Puppe, Julian: 1 article (06/2015)
4.	Sauerwald, Axel: 1 article (06/2015)
5.	Vogt, Nadine: 1 article (06/2015)
6.	Warm, Mathias: 1 article (06/2015)
7.	Butterfield, Jennifer L: 1 article (05/2013)
8.	Janfaza, Mona: 1 article (08/2012)
9.	Martin, Maureen: 1 article (08/2012)
10.	Skinner, Ruby: 1 article (08/2012)

Related Diseases

1.	Seroma 05/01/2013 - "Seroma was the most prevalent complication; the seroma rate for AlloDerm (15.7 percent) was significantly greater than that for SurgiMend (8.3 percent). "
2.	Infections 01/01/2023 - "No significant differences in infection, overall complications, or device removal rates were identified among AlloDerm, SurgiMend, and Dermacell. " 06/01/2015 - "Gross complication rates were 11.1% for SurgiMend and 40.6% for Epiflex including hematoma, postoperative skin irritation, infection, necrosis, and revision surgery. " 05/01/2013 - "No significant differences in complication rates were observed between SurgiMend and AlloDerm for hematoma, infection, major skin necrosis, or breast implant removal. "
3.	Necrosis 06/01/2015 - "Gross complication rates were 11.1% for SurgiMend and 40.6% for Epiflex including hematoma, postoperative skin irritation, infection, necrosis, and revision surgery. " 05/01/2013 - "No significant differences in complication rates were observed between SurgiMend and AlloDerm for hematoma, infection, major skin necrosis, or breast implant removal. "
4.	Hematoma 06/01/2015 - "Gross complication rates were 11.1% for SurgiMend and 40.6% for Epiflex including hematoma, postoperative skin irritation, infection, necrosis, and revision surgery. " 05/01/2013 - "No significant differences in complication rates were observed between SurgiMend and AlloDerm for hematoma, infection, major skin necrosis, or breast implant removal. "
5.	Hernia (Hernias) 08/01/2012 - "These preliminary data demonstrate promising short-term outcomes for high-risk complex hernias repaired with biologic mesh, particularly SurgiMend, but the long-term durability of these biological materials is yet to be determined."

Related Drugs and Biologics

1.	Alloderm
2.	NeoForm

Related Therapies and Procedures

1.	Device Removal (Removal, Device)
2.	Breast Implants (Breast Implant)
3.	Reoperation